Ada S. Quinn

Ada S. Quinn

Auto-generated profile, based on publicly available information

Ada S. Quinn

Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYi C. Zeng
Yi C. Zeng
MSMeghna Sobti
Meghna Sobti
AQAda Quinn
Ada Quinn
NSNicola J Smith
Nicola J Smith
SBSimon H. J. Brown
Simon H. J. Brown
ASAlastair G. Stewart
Alastair G. Stewart
Organic Cation Transporter 1 (OCT1) plays a crucial role in hepatic metabolism by mediating the uptake of a range of metabolites and drugs. Genetic variations can alter the efficacy and safety of compounds transported by OCT1, such as those used for cardiovascular, oncological, and psychological indications. Despite its importance in drug pharmacokinetics, the substrate selectivity and underlying structural mechanisms of OCT1 remain poorly understood. Here, we present cryo-EM structures of full-length human OCT1 in the inward-open conformation, both ligand-free and drug-bound, indicating the basis for its broad substrate recognition. Comparison of our structures with those of outward-open OCTs provides molecular insight into the alternating access mechanism of OCTs. We observe that hydrophobic gates stabilize the inward-facing conformation, whereas charge neutralization in the binding pocket facilitates the release of cationic substrates. These findings provide a framework for understanding the structural basis of the promiscuity of drug binding and substrate translocation in OCT1.

22 December 2023 in Journal of Neurochemistry
Verified
Journal Article
Open access
RCRyan Cantwell Chater
Ryan Cantwell Chater
AQAda S. Quinn
Ada S. Quinn
KWKatie Wilson
Katie Wilson
ZFZachary J. Frangos
Zachary J. Frangos
PSPatrick Sutton
Patrick Sutton
Robert VandenbergRobert Vandenberg
Robert Vandenberg
Glycine Transporter 2 (GlyT2) inhibitors have shown considerable potential as analgesics for the treatment of neuropathic pain but also display considerable side effects. One potential source of side effects is irreversible inhibition. In this study, we have characterized the mechanism of ORG25543 inhibition of GlyT2 by first considering three potential ligand binding sites on GlyT2—the substrate site, the vestibule allosteric site and the lipid allosteric site. The three sites were tested using a combination of molecular dynamics simulations and analysis of the inhibition of glycine transport of a series point mutated GlyT2 using electrophysiological methods. We demonstrate that the lipid allosteric site on GlyT2 is the most likely binding site for ORG25543. We also demonstrate that cholesterol derived from the cell membrane can form specific interactions with inhibitor‐bound transporters to form an allosteric network of regulatory sites. These observations will guide the future design of GlyT2 inhibitors with the objective of minimising on‐target side effects and improving the therapeutic window for the treatment of patients suffering from neuropathic pain. image

17 March 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
RMRangika Munaweera
Rangika Munaweera
AQAda Quinn
Ada Quinn
LMLuna Morrow
Luna Morrow
RMRichard A. Morris
Richard A. Morris
MOMegan L. O'Mara
Megan L. O'Mara

16 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
JPJulian Peiser-Oliver
Julian Peiser-Oliver
TPTanmay K. Pati
Tanmay K. Pati
AQAda S. Quinn
Ada S. Quinn
ILIrina Lotsaris
Irina Lotsaris
ASAzadeh Shahsavar
Azadeh Shahsavar
Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.

24 September 2025 in Polymer Chemistry
Verified
Journal Article
Open access
PDF file
SGSebastian Gillhuber
Sebastian Gillhuber
JKJochen A. Kammerer
Jochen A. Kammerer
AQAda Quinn
Ada Quinn
JHJoshua O. Holloway
Joshua O. Holloway
KMKai Mundsinger
Kai Mundsinger
Peter RoeskyPeter Roesky
Peter Roesky
The dynamic interactions of barium ions with a synthetic polymer are examined. These interactions result in the formation of intramolecularly folded single-chain nanoparticles (SCNPs), offering targeted control over the polymer morphology.

24 April 2025 in bioRxiv
Verified
Preprint
Open access
RCRyan P. Cantwell Chater
Ryan P. Cantwell Chater
JPJulian Peiser-Oliver
Julian Peiser-Oliver
TPTanmay K. Pati
Tanmay K. Pati
AQAda S. Quinn
Ada S. Quinn
ILIrina Lotsaris
Irina Lotsaris
ASAzadeh Shahsavar
Azadeh Shahsavar
Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.